Search

Your search keyword '"Souli, Maria"' showing total 338 results
Start Over Author "Souli, Maria"
338 results on '"Souli, Maria"'

1. Antibacterial Agents

Author

Souli, Maria, Poulakou, Garyfalia, Giamarellou, Helen, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D'Erme, Angelo Massimiliano, editor

Published
2023
Full Text
View/download PDF

2. Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial

Author

Tamma, Pranita D., Souli, Maria, Billard, Michael, Campbell, Joseph, Conrad, Douglas, Ellison, Damon W., Evans, Beth, Evans, Scott R., Greenwood-Quaintance, Kerryl E., Filippov, Andrey A., Geres, Holly S., Hamasaki, Toshimitsu, Komarow, Lauren, Nikolich, Mikeljon P., Lodise, Thomas P., Nayak, Seema U., Norice-Tra, Carmelle, Patel, Robin, Pride, David, Russell, Janie, Van Tyne, Daria, Chambers, Henry F., FowlerJr, Vance G., and Schooley, Robert T.

Published
2022
Full Text
View/download PDF

8. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae : Results From the INCREMENT Cohort

Author

Spanish Network for Research in Infectious Diseases (REIPI)/European Study Group of Bloodstream Infections and Sepsis (ESGBIS)/INCREMENT Group, Palacios-Baena, Zaira Raquel, Gutiérrez-Gutiérrez, Belén, Calbo, Esther, Almirante, Benito, Viale, Pierluigi, Oliver, Antonio, Pintado, Vicente, Gasch, Oriol, Martínez-Martínez, Luis, Pitout, Johann, Akova, Murat, Peña, Carmen, Gil-Bermejo, José Molina, Hernández, Alicia, Venditti, Mario, Prim, Nuria, Bou, German, Tacconelli, Evelina, Tumbarello, Mario, Hamprecht, Axel, Giamarellou, Helen, Almela, Manel, Pérez, Federico, Schwaber, Mitchell J., Bermejo, Joaquín, Lowman, Warren, Hsueh, Po-Ren, Paño-Pardo, José Ramón, Torre-Cisneros, Julián, Souli, Maria, Bonomo, Robert A., Carmeli, Yehuda, Paterson, David L., Pascual, Álvaro, and Rodríguez-Baño, Jesús

Published
2017

9. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

Author

del Toro, M D, Gálvez, J, Falcone, M, Russo, A, Giamarellou, H, Trecarichi, E M, Losito, A R, García-Vázquez, E, Hernández, A, Gómez, J, Bou, G, Iosifidis, E, Prim, N, Navarro, F, Mirelis, B, Skiada, A, Origüen, J, Juan, R San, Fernández-Ruiz, M, Larrosa, N, Puig-Asensio, M, Cisneros, J M, Molina, J, González, V, Rucci, V, de Gopegui, E Ruiz, Marinescu, C I, Martínez-Martínez, L, Fariñas, M C, Cano, M E, Gozalo, M, Mora-Rillo, M, Francisco, C Navarro-San, Peña, C, Gómez-Zorrilla, S, Tubau, F, Tsakris, A, Zarkotou, O, Antoniadou, A, Poulakou, G, Pitout, J, Virmani, D, Torre-Cisneros, J, Guzmán-Puche, J, Helvaci, Ö, Sahin, A O, Pintado, V, Ruiz, P, Bartoletti, M, Giannella, M, Tacconelli, E, Riemenschneider, F, Calbo, E, Badia, C, Xercavins, M, Gasch, O, Fontanals, D, Jové, E, Gutiérrez-Gutiérrez, Belén, Salamanca, Elena, de Cueto, Marina, Hsueh, Po-Ren, Viale, Pierluigi, Paño-Pardo, José Ramón, Venditti, Mario, Tumbarello, Mario, Daikos, George, Cantón, Rafael, Doi, Yohei, Tuon, Felipe Francisco, Karaiskos, Ilias, Pérez-Nadales, Elena, Schwaber, Mitchell J, Azap, Özlem Kurt, Souli, Maria, Roilides, Emmanuel, Pournaras, Spyros, Akova, Murat, Pérez, Federico, Bermejo, Joaquín, Oliver, Antonio, Almela, Manel, Lowman, Warren, Almirante, Benito, Bonomo, Robert A, Carmeli, Yehuda, Paterson, David L, Pascual, Alvaro, and Rodríguez-Baño, Jesús

Published
2017
Full Text
View/download PDF

11. Antibacterial Agents

Author

Souli, Maria, Giamarellou, Helen, Katsambas, Andreas D., editor, Lotti, Torello M., editor, Dessinioti, Clio, editor, and D’Erme, Angelo Massimiliano, editor

Published
2015
Full Text
View/download PDF

14. The Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group.

Author

Harris, Anthony D, Souli, Maria, Pettigrew, Melinda M, and Group, for the Antibacterial Resistance Leadership

Subjects
*DIVERSITY & inclusion policies, *COMMITTEES, *LEADERSHIP, *AWARDS, *MENTORING, *HUMAN services programs, *LABOR supply, *INTERPROFESSIONAL relations, *DRUG resistance in microorganisms, *MEDICAL fellowships, *GOAL (Psychology)
Abstract

The Antibacterial Resistance Leadership Group (ARLG) Mentoring Program was established to develop and prepare the next generation of clinician-scientists for a career in antibacterial resistance research. The ARLG Diversity, Equity, and Inclusion Working Group partners with the Mentoring Committee to help ensure diversity and excellence in the clinician-scientist workforce of the future. To advance the field of antibacterial research while fostering inclusion and diversity, the Mentoring Program has developed a number of fellowships, awards, and programs, which are described in detail in this article. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.

Author

Satlin, Michael J, Duin, David van, Tamma, Pranita D, Lodise, Thomas P, Tyne, Daria Van, Rodvold, Keith A, Rouphael, Nadine, Evans, Scott R, Fowler, Vance G, Hamasaki, Toshimitsu, Patel, Robin, Komarow, Lauren, Baum, Keri, Souli, Maria, Schwager, Nyssa, Bonomo, Robert A, Doi, Yohei, and Group, for the Antibacterial Resistance Leadership

Subjects
CEFTRIAXONE, CEFTAZIDIME, RESEARCH evaluation, ACINETOBACTER infections, COMBINATION drug therapy, LEADERSHIP, PRIORITY (Philosophy), IMMUNOCOMPROMISED patients, URINARY tract infections, CLINICAL medicine research, CARBAPENEM-resistant bacteria, ENTEROBACTERIACEAE diseases, FLUOROQUINOLONES, ANTI-infective agents, PSEUDOMONAS diseases, GRAM-negative bacterial diseases, DRUG resistance in microorganisms, AZTREONAM, ANTIBIOTICS
Abstract

Addressing the treatment and prevention of antibacterial-resistant gram-negative bacterial infections is a priority area of the Antibacterial Resistance Leadership Group (ARLG). The ARLG has conducted a series of observational studies to define the clinical and molecular global epidemiology of carbapenem-resistant and ceftriaxone-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa , and carbapenem-resistant Acinetobacter baumannii , with the goal of optimizing the design and execution of interventional studies. One ongoing ARLG study aims to better understand the impact of fluoroquinolone-resistant gram-negative gut bacteria in neutropenic patients, which threatens to undermine the effectiveness of fluoroquinolone prophylaxis in these vulnerable patients. The ARLG has conducted pharmacokinetic studies to inform the optimal dosing of antibiotics that are important in the treatment of drug-resistant gram-negative bacteria, including oral fosfomycin, intravenous minocycline, and a combination of intravenous ceftazidime-avibactam and aztreonam. In addition, randomized clinical trials have assessed the safety and efficacy of step-down oral fosfomycin for complicated urinary tract infections and single-dose intravenous phage therapy for adult patients with cystic fibrosis who are chronically colonized with P. aeruginosa in their respiratory tract. Thus, the focus of investigation in the ARLG has evolved from improving understanding of drug-resistant gram-negative bacterial infections to positively affecting clinical care for affected patients through a combination of interventional pharmacokinetic and clinical studies, a focus that will be maintained moving forward. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.

Author

Chambers, Henry F, Cross, Heather R, Souli, Maria, Evans, Scott R, Patel, Robin, Fowler, Vance G, and Group, for the Antibacterial Resistance Leadership

Subjects
LEADERSHIP, MENTORING, VANCOMYCIN, FORECASTING, DRUG resistance in microorganisms, PATIENT care, BACTERIAL diseases, ANTIBIOTICS
Abstract

In this overview, we describe important contributions from the Antibacterial Resistance Leadership Group (ARLG) to patient care, clinical trials design, and mentorship while outlining future priorities. The ARLG research agenda is focused on 3 key areas: gram-positive infections, gram-negative infections, and diagnostics. The ARLG has developed an innovative approach to clinical trials design, the desirability of outcome ranking (DOOR), which uses an ordinal measure of global outcome to assess both benefits and harms. DOOR was initially applied to observational studies to determine optimal dosing of vancomycin for methicillin-resistant Staphylcococcus aureus bacteremia and the efficacy of ceftazidime-avibactam versus colistin for the treatment of carbapenem-resistant Enterobacterales infection. DOOR is being successfully applied to the analysis of interventional trials and, in collaboration with the US Food and Drug Administration (FDA), for use in registrational trials. In the area of diagnostics, the ARLG developed Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND), an innovative design that allows simultaneous testing of multiple diagnostic platforms in a single study. This approach will be used to compare molecular assays for the identification of fluoroquinolone-resistant Neisseria gonorrhoeae (MASTER GC) and to compare rapid diagnostic tests for bloodstream infections. The ARLG has initiated a first-in-kind randomized, double-blind, placebo-controlled trial in participants with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa to assess the pharmacokinetics and antimicrobial activity of bacteriophage therapy. Finally, an engaged and highly trained workforce is critical for continued and future success against antimicrobial drug resistance. Thus, the ARLG has developed a robust mentoring program targeted to each stage of research training to attract and retain investigators in the field of antimicrobial resistance research. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group.

Author

Cross, Heather R, Greenwood-Quaintance, Kerryl E, Souli, Maria, Komarow, Lauren, Geres, Holly S, Hamasaki, Toshimitsu, Chambers, Henry F, Fowler, Vance G, Evans, Scott R, Patel, Robin, and Group, for the Antibacterial Resistance Leadership

Subjects
ANTIBIOTICS, CLINICAL pathology, COMMUNICABLE diseases, LEADERSHIP, CLINICAL medicine research, DRUG resistance, DATABASE management, HUMAN services programs, DRUG resistance in microorganisms, BACTERIAL diseases, MEDICAL research
Abstract

Developing and implementing the scientific agenda of the Antibacterial Resistance Leadership Group (ARLG) by soliciting input and proposals, transforming concepts into clinical trials, conducting those trials, and translating trial data analyses into actionable information for infectious disease clinical practice is the collective role of the Scientific Leadership Center, Clinical Operations Center, Statistical and Data Management Center, and Laboratory Center of the ARLG. These activities include shepherding concept proposal applications through peer review; identifying, qualifying, training, and overseeing clinical trials sites; recommending, developing, performing, and evaluating laboratory assays in support of clinical trials; and designing and performing data collection and statistical analyses. This article describes key components involved in realizing the ARLG scientific agenda through the activities of the ARLG centers. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Black and White Patients With Staphylococcus aureus Bacteremia Have Similar Outcomes but Different Risk Factors

Author

Ruffin, Felicia, primary, Dagher, Michael, additional, Park, Lawrence P, additional, Wanda, Lisa, additional, Hill-Rorie, Jonathan, additional, Mohnasky, Michael, additional, Marshall, Julia, additional, Souli, Maria, additional, Lantos, Paul, additional, Sharma-Kuinkel, Batu K, additional, Maskarinec, Stacey A, additional, Eichenberger, Emily M, additional, Muiruri, Charles, additional, Broadnax, Brittney, additional, and Fowler, Vance G, additional

Published
2022
Full Text
View/download PDF

23. List of Contributors

Author

Abrahamian, Fredrick M., primary, Aldape, Michael J., additional, Aldasoro, Edelweiss, additional, Allen, Upton D., additional, Al-Sum, Hythem, additional, Anadkat, Milan J., additional, Anders, Katherine, additional, Angelakis, Emmanouil, additional, Angus, Brian John, additional, Antoniadou, Anastasia, additional, Arena, Fabio, additional, Arends, Joop E., additional, Arribas, Jose R., additional, Artenstein, Andrew W., additional, Atherton, John C., additional, Aucott, John N., additional, Aw, Tar-Ching, additional, Babcock, Hilary M., additional, Bailey, Robin, additional, Bailey, Thomas C., additional, Banks, Adam Z., additional, Barillo, David J., additional, Barrette, Ernie-Paul, additional, Bauer, Martijn P., additional, Bayston, Roger, additional, Beard, C. Ben, additional, Beardsley, Justin, additional, Beeching, Nick J., additional, Bégué, Rodolfo E., additional, Beldi, Guido, additional, Benson, Constance A., additional, Berbari, Elie F., additional, Berenger, Jean-Michel, additional, Berger, Christoph, additional, Bernardino, Jose I., additional, Bille, Jacques, additional, Billioux, Alexander C., additional, Bitnun, Ari, additional, Blair, Iain, additional, Blanche, Stéphane, additional, Bleck, Thomas P., additional, Bleeker-Rovers, Chantal P., additional, Bleijenberg, Gijs, additional, Bloch, Karen C., additional, Blum, Johannes, additional, Blumberg, Emily A., additional, Bonomo, Robert A., additional, Bonten, Marc J.M., additional, Bourayou, Rafik, additional, Bouza, Emilio, additional, Brandt, K. Ashley, additional, Bretelle, Florence, additional, Brisse, Sylvain, additional, Britton, Warwick J., additional, Brook, Itzhak, additional, Brouwer, Matthijs C., additional, Browne, Sarah K., additional, Bryant, Amy E., additional, Bühler, Silja, additional, Bulger, Eileen M., additional, Buller, R. Mark L., additional, Burke, Leah A., additional, Burri, Christian, additional, Butler, Marcus W., additional, Calandra, Thierry, additional, Calfee, David P., additional, Calvo-Cano, Antonia, additional, Cameron, D. William, additional, Carcillo, Joseph A., additional, Carson, Gail, additional, Chambers, Stephen T., additional, Charrel, Remi N., additional, Nguyen, Vinh Chau Van, additional, Chevaliez, Stéphane, additional, Chiller, Tom M., additional, Christaki, Eirini, additional, Chung, Kevin K., additional, Clifford, David B., additional, Clumeck, Nathan, additional, Cohen, Jonathan, additional, Collinge, John, additional, Conlon, Christopher P., additional, Conrad, Curdin, additional, Cooke, Fiona J., additional, Cope, Jennifer Rittenhouse, additional, Corey, G. Ralph, additional, Cross, John H., additional, Cunha, Burke A., additional, Cunha, Cheston B., additional, D'Journo, Benoit, additional, Daikos, George L., additional, Daniels, Johannes M.A., additional, Davidson, Robert N., additional, Day, Nicholas P.J., additional, De Cock, Kevin M., additional, de Silva, Thushan I., additional, de Vries, Henry J.C., additional, de Wit, Stéphane, additional, Delaloye, Julie, additional, Denning, David W., additional, Dennis, David T., additional, Dhanireddy, Shireesha, additional, Dielubanza, Elodi J., additional, Diemert, David J., additional, Doganay, Mehmet, additional, Doherty, Tom, additional, Dolecek, Christiane, additional, Dondorp, Arjen M., additional, Douglas, Abby, additional, Drancourt, Michel, additional, Dubourg, Grégory, additional, Dudley, Michael N., additional, Durand, Guillaume, additional, Eckhardt, Benjamin J., additional, Efstratiou, Androulla, additional, Ekkelenkamp, Miquel B., additional, Eranki, Ambika, additional, Erdem, Hakan, additional, Escota, Gerome V., additional, Evans, Heather L., additional, Eziefula, Alice Chijioke, additional, Fenollar, Florence, additional, Fenwick, Alan, additional, Fierer, Joshua, additional, Finch, Roger G., additional, Fleckenstein, James M., additional, Forstner, Christina, additional, Foschi, Federico, additional, Fournier, Pierre-Edouard, additional, French, Martyn A., additional, Gage, Kenneth L., additional, Garcia, Lynne S., additional, Gascon, Joaquim, additional, Gastañaduy, Arturo S., additional, Gautret, Philippe, additional, Geisler, William M., additional, Ghanem, Khalil G., additional, Giani, Tommaso, additional, Giannella, Maddalena, additional, Gilliam, Bruce L., additional, Gilliet, Michel, additional, Glaser, Carol A., additional, Glupczynski, Youri, additional, Gnann, John W., additional, Goldstein, Ellie J.C., additional, Gottstein, Bruno, additional, Gouriet, Frederique, additional, Gravitt, Patti E., additional, Green, Michael D., additional, Green, Stephen T., additional, Groll, Andreas H., additional, Gulick, Roy M., additional, Gupta, Arjun, additional, Habib, Gilbert, additional, Harbarth, Stephan, additional, Harris, Marianne, additional, Hayden, Frederick G., additional, Hetem, David J., additional, Hill, Philip C., additional, Hirschel, Bernard, additional, Hodowanec, Aimee C., additional, Hoffart, Louis, additional, Hoffmann, Christian, additional, Holland, Steven M., additional, Horby, Peter W., additional, Horne, David J., additional, Hraiech, Sami, additional, Hull, Mark W., additional, Huttner, Angela, additional, Ingram, Richard J.M., additional, Islam, Jasmin, additional, Ison, Michael G., additional, James, Scott H., additional, Jenkins, Claire, additional, Jenkins, Stephen G., additional, Jensen, Jørgen Skov, additional, Johnston, Christine, additional, Jones, Theodore B., additional, Jordan, Stephen J., additional, Julian, Kathleen G., additional, Kato, Yasuyuki, additional, Kauffman, Carol A., additional, Kaye, Keith S., additional, Keane, Michael P., additional, Keeney, James, additional, Kelly, Paul, additional, Kent, Stephen J., additional, Kern, Winfried V., additional, Keynan, Yoav, additional, Kim, Andrea A., additional, Koné-Paut, Isabelle, additional, Kosmidis, Chris, additional, Kroes, Aloys C.M., additional, Kroon, Frank P., additional, Ksiazek, Thomas G., additional, Kuhlmann, F. Matthew, additional, Kuijper, Ed J., additional, Kwon, Jennie H., additional, Kyei, George B., additional, Lacombe, Karine, additional, Lagacé-Wiens, Philippe, additional, Lagier, Jean-Christophe, additional, Lamagni, Theresa, additional, Landraud, Luce, additional, Lanternier, Fanny, additional, LaPlante, Kerry L., additional, Lawn, Stephen D., additional, Lawrence, Steven J., additional, Leblebicioglu, Hakan, additional, Lee, Nelson, additional, Leggett, James E., additional, Lehours, Philippe, additional, Levy, Pierre-Yves, additional, Leyh, Rainer G., additional, Lillis, Rebecca A., additional, Limmathurotsakul, Direk, additional, Lin, Jennifer, additional, Lindquist, H.D. Alan, additional, Lipsky, Benjamin A., additional, Liscynesky, Christina, additional, Looney, David, additional, Lortholary, Olivier, additional, Lowy, Franklin D., additional, Luft, Benjamin J., additional, Mackowiak, Philip A., additional, MacPherson, Paul A., additional, Maghraoui-Slim, Valérie, additional, Mallon, Patrick W., additional, Mangino, Julie E., additional, Manuel, Oriol, additional, Marchetti, Oscar, additional, Marks, Kristen M., additional, Marr, Kieren A., additional, Marrazzo, Jeanne, additional, Marschall, Jonas, additional, Martin, David H., additional, Matonti, Frédéric, additional, Matulewicz, Richard S., additional, Mayer, Kenneth H., additional, McCulloh, Russell J., additional, McGready, Rose, additional, Mdodo, Rennatus, additional, Mead, Simon, additional, Mégraud, Francis, additional, Meintjes, Graeme, additional, Metcalf, Sarah C., additional, Michaels, Marian G., additional, Migliori, Giovanni Battista, additional, Miles, Michael A., additional, Miller, Alastair, additional, Mimiaga, Matthew J., additional, Mingeot-Leclercq, Marie-Paule, additional, Misch, Elizabeth Ann, additional, Mitreva, Makedonka, additional, Montaner, Julio S.G., additional, Moore, Caroline B., additional, Muñoz, Patricia, additional, Muñoz, Jose, additional, Murray, Clinton K., additional, Musso, Didier, additional, Mutengo, Mable, additional, Mutizwa, Misha M., additional, Naber, Kurt G., additional, Natarajan, Pavithra, additional, Neme, Santiago, additional, Newton, Paul N., additional, Nichols, Ronald A., additional, Nicolle, Lindsay E., additional, Nosten, François, additional, Notarangelo, Luigi D., additional, Nutman, Thomas B., additional, Nyirjesy, Paul, additional, O'Connell, P. Ronan, additional, Opal, Steven M., additional, Ormerod, L. Peter, additional, Osmon, Douglas R., additional, Pankert, Marie Boulze, additional, Pantaleo, Giuseppe, additional, Papazian, Laurent, additional, Parente, Diane M., additional, Parola, Philippe, additional, Parsaei, Shadi, additional, Pascual, Manuel A., additional, Patel, Rupa, additional, Patrozou, Eleni, additional, Pawlotsky, Jean-Michel, additional, Peacock, Sharon J., additional, Pechère, Jean-Claude, additional, Pelegrin, Ivan, additional, Peters, Barry S., additional, Peters, Edgar J.G., additional, Petersen, Jeannine M., additional, Petersen, Lyle R., additional, Petraitis, Vidmantas, additional, Pham, Luu-Ly, additional, Picado, Albert, additional, Pilatz, Adrian, additional, Pilmis, Benoit, additional, Pinazo, María-Jesús, additional, Pletz, Mathias W., additional, Pogue, Jason M., additional, Polgreen, Evelyn L., additional, Polgreen, Philip M., additional, Posfay-Barbe, Klara M., additional, Powderly, William G., additional, Presti, Rachel, additional, Prod'hom, Guy, additional, Puolakkainen, Mirja, additional, Quinn, Thomas C., additional, Raoult, Didier, additional, Razonable, Raymund R., additional, Read, Robert C., additional, Redfield, Robert R., additional, Rentenaar, Rob J., additional, Reynolds, Steven J., additional, Ribi, Camillo, additional, Richardson, Malcolm D., additional, Ritter, Michele L., additional, Roch, Antoine, additional, Rockstroh, Jürgen Kurt, additional, Rojek, Amanda, additional, Romero, José R., additional, Rooijakkers, Suzan H.M., additional, Rosenbluth, Daniel, additional, Rosenzweig, Sergio D., additional, Rossolini, Gian Maria, additional, Rubinstein, Ethan, additional, Ryan, Greg, additional, Safren, Steven A., additional, Sahasrabuddhe, Vikrant V., additional, Saikku, Pekka A.I., additional, Sajadi, Mohammad M., additional, Salvaggio, Michelle R., additional, Santos, Carlos A.Q., additional, Satlin, Michael J., additional, Schaeffer, Anthony J., additional, Schimmer, Christoph, additional, Schooley, Robert T., additional, Schumacher, Richard F., additional, Sha, Beverly E., additional, Shapiro, Daniel S., additional, Sheehan, Gerard, additional, Shlaes, David M., additional, Shoham, Shmuel, additional, Simmons, Cameron P., additional, Simon, Dennis W., additional, Simon, Matthew S., additional, Simonsen, Kari A., additional, Slack, Mary P.E., additional, Smith, Tyrel T., additional, Sobel, Jack D., additional, Souli, Maria, additional, Sridhar, Shruti, additional, Steckelberg, James M., additional, Stevens, Dennis L., additional, Strah, Heather, additional, Sturm, A. Willem, additional, Sungkanuparph, Somnuek, additional, Tabrizi, Sarah J., additional, Tacconelli, Evelina, additional, Tan, Chen Sabrina, additional, Taplitz, Randy A., additional, Thomas, Guillemette, additional, Thomas, Lora D., additional, Thuny, Franck, additional, Thwaites, Guy, additional, Tissot, Frederic, additional, Tønjum, Tone, additional, Torriani, Francesca J., additional, Toso, Christian, additional, Tulkens, Paul M., additional, Tunkel, Allan R., additional, Turner, Claire E., additional, Ustianowski, Andrew P., additional, van Bambeke, Françoise, additional, van Crevel, Reinout, additional, van de Beek, Diederik, additional, van Delden, Christian, additional, van der Eerden, Menno M., additional, van der Meer, Jos W.M., additional, van der Poll, Tom, additional, van Ingen, Jakko, additional, van Putten, Jos, additional, Vaudaux, Bernard P., additional, Vermund, Sten H., additional, Viscidi, Raphael P., additional, Visvanathan, Kumar, additional, Visvesvara, Govinda S., additional, von Seidlein, Lorenz, additional, Wagenlehner, Florian M.E., additional, Wald, Anna, additional, Walsh, Thomas J., additional, Warhurst, David C., additional, Warnock, David W., additional, Warrell, David A., additional, Warrell, Mary J., additional, Warris, Adilia, additional, Watkins, Richard R., additional, Weatherall, David J., additional, Weber, Rainer, additional, Weidner, Wolfgang, additional, White, Jonathan R., additional, White, Peter J., additional, Whitehorn, James, additional, Whitley, Richard J., additional, Whitty, Christopher J.M., additional, Wiersinga, Willem Joost, additional, Wilcox, Mark H., additional, Williams, Thomas N., additional, Wilson, Cara C., additional, Wilson, Mary Elizabeth, additional, Wisplinghoff, Hilmar, additional, Wood, Robin, additional, Wunderink, Richard G., additional, Wyles, David, additional, Yang, Zhi-Tao, additional, Yoder, Jonathan S., additional, Zaidi, Najam A., additional, Zimmer, Andrea J., additional, Zuckerman, Jane N., additional, and Zumla, Alimuddin, additional

Published
2017
Full Text
View/download PDF

24. Success stories about severe pneumonia caused by Panton–Valentine leucocidin-producing Staphylococcus aureus

Author

Paramythiotou Elisabeth, Souli Maria, Galani Irene, Giamarellou Helen, and Armaganidis Apostolos

Subjects
Infectious and parasitic diseases, RC109-216, Microbiology, QR1-502
Abstract

We describe three cases of community-acquired necrotizing pneumonia which were caused by Panton–Valentine leucocidin-producing strains of Staphylococcus aureus (one of them methicillin sensitive). All cases were successfully treated without any sequelae for the patients due to the prompt initiation of adequate antimicrobial therapy. High suspicion toward this fatal pathogen was the key to the successful outcome of the patients. Keywords: Community-acquired pneumonia, Clindamycin, Staphylococcus aureus, Panton–Valentine leukocidin

Published
2014
Full Text
View/download PDF

27. Black and White Patients With Staphylococcus aureus Bacteremia Have Similar Outcomes but Different Risk Factors.

Author

Ruffin, Felicia, Dagher, Michael, Park, Lawrence P, Wanda, Lisa, Hill-Rorie, Jonathan, Mohnasky, Michael, Marshall, Julia, Souli, Maria, Lantos, Paul, Sharma-Kuinkel, Batu K, Maskarinec, Stacey A, Eichenberger, Emily M, Muiruri, Charles, Broadnax, Brittney, and Fowler, Vance G

Subjects
STAPHYLOCOCCAL disease treatment, BACTEREMIA, MULTIPLE regression analysis, RACE, HEALTH outcome assessment, STAPHYLOCOCCAL diseases, RISK assessment, DESCRIPTIVE statistics, LONGITUDINAL method, DISEASE complications, SYMPTOMS
Abstract

Background Staphylococcus aureus bacteremia (SAB) disproportionately affects Black patients. The reasons for this disparity are unclear. Methods We evaluated a prospectively ascertained cohort of patients with SAB from 1995 to 2020. Clinical characteristics, bacterial genotypes, and outcome were compared among Black and White patients with SAB. Multivariable logistic regression models were used to determine factors independently associated with the outcomes. Results Among 3068 patients with SAB, 1107 (36%) were Black. Black patients were younger (median, 56 years vs 63 years; P <.001) and had higher rates of diabetes (47.5% vs 34.5%, P <.001), hemodialysis dependence (40.0% vs 7.3%, P <.001), and human immunodeficiency virus (6.4% vs 0.6%, P <.001). Black patients had higher rates of methicillin-resistant S. aureus (49.3% vs 44.9%, P =.020), including the USA300 hypervirulent clone (11.5% vs 8.4%, P =.007). White patients had higher rates of corticosteroid use (22.4% vs 15.8%, P <.0001) and surgery in the preceding 30 days (28.1% vs 18.7%, P <.001). Although the median Acute Physiology Score (APS) at the time of initial SAB diagnosis was significantly higher in Black patients (median APS, 9; interquartile range [IQR], 5–14 vs median APS, 7; IQR, 4–12; P <.001), race was not associated with 90-day mortality (risk ratio, 1.02; 95% confidence interval,.93–1.12), and rates of metastatic infection were lower among Black patients (37.2% vs 41.3% White, P =.029). Conclusions Despite differences in Black patients' higher APS on presentation and more risk factors, including a 5 times higher risk of hemodialysis dependence, 90-day mortality among Black and White patients with SAB was similar. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Requirements for Designing an Effective Metallic Nanoparticle (NP)-Boosted Radiation Therapy (RT)

Author

Tremi, Ioanna Spyratou, Ellas Souli, Maria Efstathopoulos, Efstathios P. Makropoulou, Mersini Georgakilas, Alexandros G. and Sihver, Lembit

Abstract

Simple Summary Recent advances in nanotechnology gave rise to trials with various types of metallic nanoparticles (NPs) to enhance the radiosensitization of cancer cells while reducing or maintaining the normal tissue complication probability during radiation therapy. This work reviews the physical and chemical mechanisms leading to the enhancement of ionizing radiation’s detrimental effects on cells and tissues, as well as the plethora of experimental procedures to study these effects of the so-called “NPs’ radiosensitization”. The paper presents the need to a better understanding of all the phases of actions before applying metallic-based NPs in clinical practice to improve the effect of IR therapy. More physical and biological experiments especially in vivo must be performed and simulation Monte Carlo or mathematical codes based on more accurate models for all phases must be developed. Many different tumor-targeted strategies are under development worldwide to limit the side effects and improve the effectiveness of cancer therapies. One promising method is to enhance the radiosensitization of the cancer cells while reducing or maintaining the normal tissue complication probability during radiation therapy using metallic nanoparticles (NPs). Radiotherapy with MV photons is more commonly available and applied in cancer clinics than high LET particle radiotherapy, so the addition of high-Z NPs has the potential to further increase the efficacy of photon radiotherapy in terms of NP radiosensitization. Generally, when using X-rays, mainly the inner electron shells are ionized, which creates cascades of both low and high energy Auger electrons. When using high LET particles, mainly the outer shells are ionized, which give electrons with lower energies than when using X-rays. The amount of the produced low energy electrons is higher when exposing NPs to heavy charged particles than when exposing them to X-rays. Since ions traverse the material along tracks, and therefore give rise to a much more inhomogeneous dose distributions than X-rays, there might be a need to introduce a higher number of NPs when using ions compared to when using X-rays to create enough primary and secondary electrons to get the desired dose escalations. This raises the questions of toxicity. This paper provides a review of the fundamental processes controlling the outcome of metallic NP-boosted photon beam and ion beam radiation therapy and presents some experimental procedures to study the biological effects of NPs’ radiosensitization. The overview shows the need for more systematic studies of the behavior of NPs when exposed to different kinds of ionizing radiation before applying metallic-based NPs in clinical practice to improve the effect of IR therapy.

Published
2021

35. An outbreak of infection due to (beta)-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes

Author

Souli, Maria, Galani, Irene, Antoniadou, Anastasia, Papadomichelakis, Evangelos, Poulakou, Garyphallia, Panagea, Theofano, Vourli, Sofia, Zerva, Loukia, Armaganidis, Apostolos, Kanellakopoulou, Kyriaki, and Giamarellou, Helen

Subjects
Klebsiella -- Distribution, Klebsiella -- Identification and classification, Bacterial pneumonia -- Distribution, Bacterial pneumonia -- Care and treatment, Bacterial pneumonia -- Patient outcomes, Bacterial pneumonia -- Research, Pneumonia -- Distribution, Pneumonia -- Care and treatment, Pneumonia -- Patient outcomes, Pneumonia -- Research, Beta lactamases -- Identification and classification, Company distribution practices, Health, Health care industry
Published
2010

36. Clinical experience of serious infections caused by enterobacteriaceae producing VIM-1 metallo-[beta]-lactamase in a Greek University Hospital

Author

Souli, Maria, Kontopidou, Flora V., Papadomichelakis, Evangelos, Galani, Irene, Armaganidis, Apostolos, and Giamarellou, Helen

Subjects
Beta lactamases -- Research, Enterobacteriaceae infections -- Development and progression, Enterobacteriaceae infections -- Patient outcomes, Enterobacteriaceae infections -- Research, Enterobacter -- Identification and classification, Enterobacteriaceae -- Identification and classification, Health, Health care industry
Published
2008

37. Antibacterial Resistance Leadership Group 2.0: Back to Business

Author

Chambers, Henry F, primary, Evans, Scott R, additional, Patel, Robin, additional, Cross, Heather R, additional, Harris, Anthony D, additional, Doi, Yohei, additional, Boucher, Helen W, additional, van Duin, David, additional, Tsalik, Ephraim L, additional, Holland, Thomas L, additional, Pettigrew, Melinda M, additional, Tamma, Pranita D, additional, Hodges, Kathryn R, additional, Souli, Maria, additional, and Fowler, Vance G, additional

Published
2021
Full Text
View/download PDF

42. Characterization of 16S rRNA methylase genes in Enterobacterales and Pseudomonas aeruginosa in Athens Metropolitan area, 2015–2016

Author

Nafplioti, Konstantina, primary, Souli, Maria, additional, Adamou, Panagiota, additional, Moraitou, Eleni, additional, Giannopoulou, Panagiota, additional, Chra, Paraskevi, additional, Damala, Maria, additional, Vogiatzakis, Evangelos, additional, Trikka-Graphakos, Eleftheria, additional, Baka, Vasiliki, additional, Prifti, Eleni, additional, Antoniadou, Anastasia, additional, and Galani, Irene, additional

Published
2020
Full Text
View/download PDF

44. Risk Factors for Recurrent Staphylococcus aureus Bacteremia

Author

Choi, Seong-Ho, primary, Dagher, Michael, additional, Ruffin, Felicia, additional, Park, Lawrence P, additional, Sharma-Kuinkel, Batu K, additional, Souli, Maria, additional, Morse, Alison M, additional, Eichenberger, Emily M, additional, Hale, Lauren, additional, Kohler, Celia, additional, Warren, Bobby, additional, Hansen, Brenda, additional, Medie, Felix Mba, additional, McIntyre, Lauren M, additional, and Fowler, Vance G, additional

Published
2020
Full Text
View/download PDF

45. In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece

Author

Galani, Irene, primary, Papoutsaki, Vassiliki, primary, Karantani, Irene, primary, Karaiskos, Ilias, primary, Galani, Lamprini, primary, Adamou, Panagiota, primary, Deliolanis, Ioannis, primary, Kodonaki, Antigoni, primary, Papadogeorgaki, Eleni, primary, Markopoulou, Margarita, primary, Maraki, Sofia, primary, Damala, Maria, primary, Prifti, Eleni, primary, Vagiakou, Eleni, primary, Petinaki, Efthimia, primary, Fountoulis, Kimon, primary, Tsiplakou, Sophia, primary, Kirikou, Helen, primary, Souli, Maria, primary, Antoniadou, Anastasia, primary, and Giamarellou, Helen, primary

Published
2020
Full Text
View/download PDF

47. Dissemination of International Clone IIAcinetobacter baumanniiStrains Coproducing OXA-23 Carbapenemase and 16S rRNA Methylase ArmA in Athens, Greece

Author

Nafplioti, Konstantina, primary, Galani, Irene, additional, Angelidis, Evdokia, additional, Adamou, Panagiota, additional, Moraitou, Eleni, additional, Giannopoulou, Panagiota, additional, Chra, Paraskevi, additional, Damala, Maria, additional, Vogiatzakis, Evangellos, additional, Trikka-Graphakos, Eleftheria, additional, Baka, Vasiliki, additional, Prifti, Eleni, additional, Antoniadou, Anastasia, additional, and Souli, Maria, additional

Published
2020
Full Text
View/download PDF

49. Additional file 1: of Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance

Author

Galani, Irene, Nafplioti, Konstantina, Adamou, Panagiota, Karaiskos, Ilias, Giamarellou, Helen, and Souli, Maria

Abstract

Table S1. Additional table includes sequences of primers used for simplex and multiplex PCRs for the detection of genes encoding aminoglycoside modifying enzyme and 16S rRNA methyltransferase genes in Î . pneumoniae. (DOCX 19â kb)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results